GetTopicDetailResponse(id=b7f513e9c0, topicName=5-FU, introduction=5-FU, content=null, image=null, comments=1, allHits=1801, url=https://h5.medsci.cn/topic?id=1379, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=1920, tagList=[TagDto(tagId=1920, tagName=5-FU)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2218405, encodeId=8b3e22184056e, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#結(jié)直腸癌#</a> <a href='/topic/show?id=0a9e922085f' target=_blank style='color:#2F92EE;'>#貝伐珠單抗#</a> <a href='/topic/show?id=b7f513e9c0' target=_blank style='color:#2F92EE;'>#5-FU#</a> <a href='/topic/show?id=9a1511e5088b' target=_blank style='color:#2F92EE;'>#三聯(lián)化療#</a>, objectTitle=JAMA Netw. Open ：結(jié)直腸癌患者三聯(lián)化療加貝伐珠單抗中低劑量 5-FU 與高劑量 5-FU 的比較, objectType=article, longId=837549, objectId=3d0083e549a5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240804/1722739947127_6145188.jpg, objectUrl=/article/show_article.do?id=3d0083e549a5, replyNumber=0, likeNumber=152, createdTime=2024-08-04, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3d0083e549a5, moduleTitle=JAMA Netw. Open ：結(jié)直腸癌患者三聯(lián)化療加貝伐珠單抗中低劑量 5-FU 與高劑量 5-FU 的比較, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3d0083e549a5)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=899374, encodeId=8e3e8993e443, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>新藥不多，仍然以<a href='/topic/show?id=b7f513e9c0' target=_blank style='color:#2F92EE;'>#5-FU#</a>為基礎(chǔ)進(jìn)行改進(jìn)為主, objectTitle=消化道腫瘤新藥:TAS-102,再下一城, objectType=article, longId=140144, objectId=f893140144b7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201806/20180606120716500.jpg, objectUrl=/article/show_article.do?id=f893140144b7, replyNumber=0, likeNumber=215, createdTime=2020-11-15, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f893140144b7, moduleTitle=消化道腫瘤新藥:TAS-102,再下一城, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f893140144b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
